Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
Conditions
Prostate Cancer
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Stanford University Medical Center, Palo Alto, California, United States
Contact: Principal Investigator (Hong Song)Sansum Clinic, Santa Barbara, California, United States
Contact: Principal Investigator (Mukul Gupta)Rocky Mountain Cancer Centers, Denver, Colorado, United States
Contact: Principal Investigator (Allen Cohn)Baptist Health South, Miami, Florida, United States
Contact: Principal Investigator (Rohan Garje)AdventHealth, Orlando, Florida, United States
Contact: Principal Investigator (Ravi Shridhar)Northwestern University, Chicago, Illinois, United States
Contact: Study coordinator (Rachel Hanna Springsdorf) · rachelspringsdorf@northwestern.edu · +1 312 695 1382Contact: Principal Investigator (Maha Hussain)Univ Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States
Contact: Principal Investigator (Kristin Plichta)University of Kansas Hospital, Kansas City, Kansas, United States
Contact: Principal Investigator (Xinglei Shen)East Jefferson Hospital, Metairie, Louisiana, United States
Contact: Principal Investigator (Alton Oliver Sartor)Dana Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Principal Investigator (Xiao Wei)Wash U School of Medicine, St Louis, Missouri, United States
Contact: Principal Investigator (Jeff Michalski)Nebraska Cancer Specialists, Omaha, Nebraska, United States
Contact: Principal Investigator (Samuel Mehr)New Jersey Urology LLC, Voorhees Township, New Jersey, United States
Contact: Principal Investigator (Gordon Brown)Bassett Medical Center, Cooperstown, New York, United States
Contact: Principal Investigator (Timothy Korytko)Weill Cornell Medicine NY-Presb, New York, New York, United States
Contact: Principal Investigator (Scott Tagawa)University of Rochester Medical Ctr, Rochester, New York, United States
Contact: Principal Investigator (Haoming Carl Qiu)Associated Med Professionals of NY, Syracuse, New York, United States
Contact: Principal Investigator (Steven Finkelstein)Montefiore Medical Center, The Bronx, New York, United States
Contact: Principal Investigator (Benjamin A Gartrell)Central Ohio Urology Group, Gahanna, Ohio, United States
Contact: Principal Investigator (Benjamin Martin)MUSC Hollings Cancer Center, Charleston, South Carolina, United States
Contact: Principal Investigator (Kevin Becker)Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States
Contact: Principal Investigator (Neal D Shore)Urology San Antonio, San Antonio, Texas, United States
Contact: Principal Investigator (Daniel Saltzstein)Woodlands Cancer Institute American Oncology Partners, The Woodlands, Texas, United States
Contact: Principal Investigator (Jason Berilgen)Swedish Medical Center, Seattle, Washington, United States
Contact: Principal Investigator (Song Zhao)Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Contact: Principal Investigator (Deepak Kilari)Novartis Investigative Site, Darlinghurst, New South Wales, Australia
Novartis Investigative Site, Adelaide, South Australia, Australia
Novartis Investigative Site, São Paulo, São Paulo, Brazil
Novartis Investigative Site, São Paulo, São Paulo, Brazil
Novartis Investigative Site, Fuzhou, Fujian, China
Novartis Investigative Site, Guangzhou, Guangdong, China
Novartis Investigative Site, Wuhan, Hubei, China
Novartis Investigative Site, Wuhan, Hubei, China
Novartis Investigative Site, Nanjing, Jiangsu, China
Novartis Investigative Site, Nanjing, Jiangsu, China
Novartis Investigative Site, Shenyang, Liaoning, China
Novartis Investigative Site, Chengdu, Sichuan, China
Novartis Investigative Site, Hangzhou, Zhejiang, China
Novartis Investigative Site, Beijing, China
Novartis Investigative Site, Beijing, China
Novartis Investigative Site, Guangzhou, China
Novartis Investigative Site, Shanghai, China
Novartis Investigative Site, Shanghai, China
Novartis Investigative Site, Shanghai, China
Novartis Investigative Site, Tianjin, China
Novartis Investigative Site, Hong Kong, Hong Kong
Novartis Investigative Site, Gurgaon, Haryana, India
Novartis Investigative Site, Bengaluru, Karnataka, India
Novartis Investigative Site, Mumbai, Maharashtra, India
Novartis Investigative Site, Sapporo, Hokkaido, Japan
Novartis Investigative Site, Kobe, Hyōgo, Japan
Novartis Investigative Site, Kobe, Hyōgo, Japan
Novartis Investigative Site, Yokohama, Kanagawa, Japan
Novartis Investigative Site, Chuo Ku, Tokyo, Japan
Novartis Investigative Site, Chiba, Japan
Novartis Investigative Site, Fukuoka, Japan
Novartis Investigative Site, Fukuoka, Japan
Novartis Investigative Site, Fukuoka, Japan
Novartis Investigative Site, Fukushima, Japan
Novartis Investigative Site, Hiroshima, Japan
Novartis Investigative Site, Kyoto, Japan
Novartis Investigative Site, Singapore, Singapore
Novartis Investigative Site, Singapore, Singapore
Novartis Investigative Site, Singapore, Singapore
Novartis Investigative Site, Seoul, South Korea
Novartis Investigative Site, Seoul, South Korea
Novartis Investigative Site, Kaohsiung City, Taiwan
Novartis Investigative Site, Taipei, Taiwan
Novartis Investigative Site, Taoyuan, Taiwan
Novartis Investigative Site, Sutton, Surrey, United Kingdom
Study leads
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals